History of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The TME is immunosuppressive, thus rendering the immune system less effective in killing cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Goycoolea, A. (1997) · Cited by 3,615
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., & Isner, J. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3964 · Cited by 1,856
Research works printed but not linked: 1
- Sonnenfeld A Leukamische reaktiones bei carcinoma Zeitschrift f Klin Med 1929 111
Cited by
Items 101–200 of 1,000
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 167
Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance
Kishimoto, T. K., & Maldonado, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00230 · Cited by 167
Germann, M., Zangger, N., Sauvain, M., Sempoux, C., Bowler, A. D., Wirapati, P., Kandalaft, L. E., Delorenzi, M., Tejpar, S., Coukos, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910681 · Cited by 164
Antuamwine, B. B., Bosnjakovic, R., Hofmann-Vega, F., Wang, X., Θεοδοσίου, Θ., Iliopoulos, I., & Brandau, S. (2022) · Immunological Reviews · doi:10.1111/imr.13176 · Cited by 178
Montalbán del Barrio, I., Penski, C., Schlahsa, L., Stein, R. G., Diessner, J., Wöckel, A., Dietl, J., Lutz, M. B., Mittelbronn, M., Wischhusen, J., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0154-9 · Cited by 154
Haverkamp, J. M., Smith, A. M., Weinlich, R., Dillon, C. P., Qualls, J. E., Neale, G., Koss, B., Kim, Y., Bronte, V., Herold, M. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.020 · Cited by 167
Nuclear receptors: recent drug discovery for cancer therapies
Zhao, L., Zhou, S., & Gustafsson, J.-Α. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00222 · Cited by 190
Mechanisms underlying immunosuppression by regulatory cells
Goldmann, O., Nwofor, O. V., Chen, Q., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328193 · Cited by 173
In vivo capture and label-free detection of early metastatic cells
Azarin, S. M., Yi, J., Gower, R. M., Aguado, B. A., Sullivan, M. E., Goodman, A. G., Jiang, E. J., Rao, S. S., Ren, Y., Tucker, S. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms9094 · Cited by 161
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Knaul, J. K., Jörg, S., Oberbeck‐Müller, D., Heinemann, E., Scheuermann, L., Brinkmann, V., Mollenkopf, H., Yeremeev, V., Kaufmann, S. H. E., & Dorhoi, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0828oc · Cited by 174
STAT3 in cancer: A double edged sword
Avalle, L., Camporeale, A., Camperi, A., & Poli, V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.03.018 · Cited by 169
Intertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine
La-Beck, N. M., Islam, M. R., & Markiewski, M. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603039 · Cited by 174
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 170
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 152
Erratum: Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.178 · Cited by 153
Martinson, H. A., Jindal, S., Durand‐Rougely, C., Borges, V. F., & Schedin, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29181 · Cited by 149
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 147
Heim, C. E., Vidlak, D., Scherr, T. D., Hartman, C. W., Garvin, K. L., & Kielian, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402689 · Cited by 148
Cysteine Cathepsins in Tumor-Associated Immune Cells
Jakoš, T., Pišlar, A. H., Jewett, A., & Kos, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02037 · Cited by 158
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 162
Gordon-Weeks, A. N., Lim, S. Y., Yuzhalin, A. E., Jones, K. I., Markelc, B., Kim, K. J., Buzzelli, J. N., Fokas, E., Cao, Y., Smart, S., et al. (2017) · Hepatology · doi:10.1002/hep.29088 · Cited by 153
Clostridium novyi-NT in cancer therapy
Staedtke, V., Roberts, N. J., Bai, R.-Y., & Zhou, S. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.01.003 · Cited by 153
Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections
Dorhoi, A., & du Plessis, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01895 · Cited by 153
The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis
Itatani, Y., Kawada, K., Inamoto, S., Yamamoto, T., Ogawa, R., Taketo, M., & Sakai, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050643 · Cited by 132
Tumour microenvironment responsive nanoconstructs for cancer theranostic
Gulzar, A., Xu, J., Wang, C., He, F., Yang, D., Gai, S., Yang, P., Lin, J., Jin, D., & Xing, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.03.007 · Cited by 139
Inamoto, S., Itatani, Y., Yamamoto, T., Minamiguchi, S., Hirai, H., Iwamoto, M., Hasegawa, S., Taketo, M. M., Sakai, Y., & Kawada, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0726 · Cited by 135
Tolerance in the Age of Immunotherapy
Bluestone, J. A., & Anderson, M. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1911109 · Cited by 149
Wang, X., Ding, H., Li, Z., Peng, Y., Tan, H. F., Wang, C., Huang, G., Li, W., Ma, G., & Wei, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00894-3 · Cited by 144
Ruan, R., Li, L., Li, X., Huang, C., Zhanmin, Z., Zhong, H., Zeng, S., Shi, Q., Yang, X., Zeng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01761-7 · Cited by 143
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
Chafe, S. C., Lou, Y., Sceneay, J., Vallejo, M., Hamilton, M. J., McDonald, P. C., Bennewith, K. L., Möller, A., & Dedhar, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3000 · Cited by 134
F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner
Yumimoto, K., Akiyoshi, S., Ueo, H., Sagara, Y., Onoyama, I., Ueo, H., Ohno, S., Mori, M., Mimori, K., & Nakayama, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78782 · Cited by 143
Targeting myeloid cells in the tumor sustaining microenvironment
Schupp, J., Krebs, F. K., Zimmer, N., Trzeciak, E., Schuppan, D., & Tuettenberg, A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.013 · Cited by 126
Hu, J., Zhao, Q., Kong, L.-Y., Wang, J., Yan, J., Xia, X., Jia, Z., Heimberger, A. B., & Li, S. (2021) · Science Advances · doi:10.1126/sciadv.abc2511 · Cited by 126
Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies
Yasmeen, F., Pirzada, R. H., Ahmad, B., Choi, B., & Choi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147666 · Cited by 150
Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity
Pawelec, G., Verschoor, C. P., & Ostrand‐Rosenberg, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01099 · Cited by 140
Adeshakin, A. O., Liu, W., Adeshakin, F. O., Afolabi, L. O., Zhang, M., Zhang, G., Wang, L., Li, Z., Lin, L., Cao, Q., et al. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104286 · Cited by 134
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 123
Vetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
“In the latter, MDSCs acquire a far more suppressive ability, with the M-MDSC population and the classical activated monocytes (M1) rapidly evolving into tumor-associated macrophages (TAMs), while the neutrophils tend to transform in a more suppressive subpopulation, the tumor-associated neutrophils (TANs) [1,15,21].”
BackgroundInfluentialSalminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 120
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Swamydas, M., Murphy, E. V., Ignatz-Hoover, J. J., Malek, E., & Driscoll, J. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01234-2 · Cited by 133
Guillerey, C., Nakamura, K., Vučković, S., Hill, G. R., & Smyth, M. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2135-z · Cited by 129
Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer
Ren, W., Zhang, X., Li, W., Feng, Q., Feng, H., Tong, Y., Rong, H., Wang, W., Zhang, D., Zhang, Z., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s198886 · Cited by 126
Dinh, H. Q., Eggert, T., Meyer, M. A., Zhu, Y. P., Olingy, C. E., Llewellyn, R., Wu, R., & Hedrick, C. C. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.017 · Cited by 118
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 120
Leukocyte trafficking in tumor microenvironment
Prete, A. D., Schioppa, T., Tiberio, L., Stabile, H., & Sozzani, S. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.004 · Cited by 136
Shien, K., Papadimitrakopoulou, V. A., & Wistuba, I. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.016 · Cited by 124
Nan, J., Xing, Y., Hu, B., Tang, J., Dong, H., He, Y., Ruan, D., Ye, Q., Cai, J., Ma, X., et al. (2017) · Immunology · doi:10.1111/imm.12876 · Cited by 128
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
“MDSCs The phenomenon that tumor can induce myelopoiesis has been observed for more than 100 years [72].”
BackgroundStromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 120
Hollen, M. K., Stortz, J. A., Darden, D. B., Dirain, M. L. S., Nacionales, D. C., Hawkins, R. B., Cox, M. C., Lopez, M.-C., Rincon, J. C., Ungaro, R. F., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2628-x · Cited by 125
The Generation and Identity of Human Myeloid-Derived Suppressor Cells
Bergenfelz, C., & Leandersson, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00109 · Cited by 125
Ku, A. W., Muhitch, J. B., Powers, C. A., Diehl, M. R., Kim, M., Fisher, D. T., Sharda, A. P., Clements, V. K., O’Loughlin, K. L., Minderman, H., et al. (2016) · eLife · doi:10.7554/elife.17375 · Cited by 120
Zhao, D., Cai, L., Lü, X., Liang, X., Li, J., Chen, P., Ittmann, M., Shang, X., Jiang, S., Li, H., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1352 · Cited by 123
Zhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 125
Myeloid-Derived Suppressor Cells in the Development of Lung Cancer
Ortiz, M. L., Lu, L., Ramachandran, I., & Gabrilovich, D. I. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0129 · Cited by 110
Self-citationFunctional Immune Anatomy of the Liver—As an Allograft
Demetris, A. J., Bellamy, C. O. C., Gandhi, C. R., Prost, S., Nakanuma, Y., & Stolz, D. B. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13749 · Cited by 115
Yang, Q., Nanayakkara, G., Drummer, C., Sun, Y., Johnson, C., Cueto, R., Fu, H., Shao, Y., Wang, L., Yang, W. Y., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00818 · Cited by 123
Papaspyridonos, M., Matei, I., Huang, Y., do Rosario Andre, M., Brazier-Mitouart, H., Waite, J. C., Chan, A. S., Kalter, J., Ramos, I., Wu, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7840 · Cited by 116
Ai, L., Mu, S., Wang, Y., Wang, H., Cai, L., Li, W., & Hu, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-5086-y · Cited by 116
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 126
Chen, L., Li, J., Wang, F., Dai, C., Wu, F., Liu, X., Li, T., Glauben, R., Zhang, Y., Nie, G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1114 · Cited by 101
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Myeloid-Derived Suppressor Cells in Solid Tumors
Ma, T., Renz, B. W., Ilmer, M., Koch, D. T., Yang, Y., Werner, J., & Bazhin, A. V. (2022) · Cells · doi:10.3390/cells11020310 · Cited by 122
Salemme, V., Centonze, G., Avalle, L., Natalini, D., Piccolantonio, A., Arina, P., Morellato, A., Ala, U., Taverna, D., Turco, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170264 · Cited by 123
Xiao, P., Wan, X., Cui, B., Liu, Y., Qiu, C., Rong, J., Zheng, M., Song, Y., Chen, L., He, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1063772 · Cited by 117
A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans
Gustafson, M. P., Lin, Y., Maas, M. L., Keulen, V. P. V., Johnston, P. B., Peikert, T., Gastineau, D. A., & Dietz, A. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121546 · Cited by 114
ZEB 1‐regulated inflammatory phenotype in breast cancer cells
Katsura, A., Tamura, Y., Hokari, S., Harada, M., Morikawa, M., Sakurai, T., Takahashi, K., Mizutani, A., Nishida, J., Yokoyama, Y., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12098 · Cited by 124
Komura, N., Mabuchi, S., Shimura, K., Yokoi, E., Kozasa, K., Kuroda, H., Takahashi, R., Sasano, T., Kawano, M., Matsumoto, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02628-2 · Cited by 114
Flores, R. R., Clauson, C. L., Cho, J., Lee, B.-C., McGowan, S. J., Baker, D. J., Niedernhofer, L. J., & Robbins, P. D. (2017) · Aging Cell · doi:10.1111/acel.12571 · Cited by 107
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2175-3 · Cited by 102
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells
Alissafi, T., Hatzioannou, A., Mintzas, K., Barouni, R. M., Banos, A., Sormendi, S., Polyzos, A., Xilouri, M., Wielockx, B., Gogas, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120888 · Cited by 117
The influence of microenvironment on tumor immunotherapy
Zhang, J., Shi, Z., Xu, X., Yu, Z., & Mi, J. (2019) · FEBS Journal · doi:10.1111/febs.15028 · Cited by 118
Myeloid-derived suppressor cells and their role in pancreatic cancer
Pergamo, M., & Miller, G. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.65 · Cited by 115
Tebartz, C., Horst, S. A., Sparwasser, T. D., Huehn, J., Beineke, A., Peters, G., & Medina, E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400196 · Cited by 120
Tian, X., Ma, J., Wang, T., Tian, J., Zhang, Y., Mao, L., Xu, H., & Wang, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00473 · Cited by 114
Lu, Y., Miao, L., Wang, Y., Xu, Z., Zhao, Y. D., Shen, Y., Xiang, G., & Huang, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.165 · Cited by 116
Li, D., Shi, G., Wang, J., Zhang, D., Pan, Y., Dou, H., & Hou, Y. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1876-0 · Cited by 108
Ansems, M., & Span, P. N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.001 · Cited by 116
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 117
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 100
Myeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy
Yin, Z., Li, C., Wang, J., & Xue, L. (2019) · International Journal of Cancer · doi:10.1002/ijc.31744 · Cited by 101
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 107
Tumour progression and metastasis
Arvelo, F. A., Sojo, F. J., & Cotte, C. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.617 · Cited by 114
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
Ham, B., Wang, N., D'Costa, Z., Fernández, M. C., Bourdeau, F., Auguste, P., Illemann, M., Eefsen, R. L., Høyer‐Hansen, G., Vainer, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3173 · Cited by 102
Yu, B., Luo, F., Sun, B., Liu, W., Shi, Q., Cheng, S., Chen, C., Chen, G., Li, Y., & Feng, H. (2021) · Advanced Science · doi:10.1002/advs.202100014 · Cited by 110
The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
Pimenta, D. B., Varela, V. A., Datoguia, T. S., Caraciolo, V. B., Lopes, G. H., & Pereira, W. O. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764698 · Cited by 106
The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression
Wagner, K., Cherfils‐Vicini, J., Hosen, N., Hohenstein, P., Gilson, É., Hastie, N. D., Michiels, J., & Wagner, N. (2014) · Nature Communications · doi:10.1038/ncomms6852 · Cited by 104
Li, X., Lu, Q., Chen, W., Xu, W. B., Liu, R., Zhang, S.-F., Du, J., Li, H., Yao, K., Zhai, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat4162 · Cited by 100
The Endless Saga of Monocyte Diversity
Canè, S., Ugel, S., Trovato, R., Marigo, I., Sanctis, F. D., Sartoris, S., & Bronte, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01786 · Cited by 107
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 104
Shi, H., Zhang, J., Han, X., Li, H., Xie, M., Sun, Y., Liu, W., Ba, X., & Zeng, X. (2016) · International Journal of Cancer · doi:10.1002/ijc.30538 · Cited by 106
The Pseudogene Olfr29-ps1 Promotes the Suppressive Function and Differentiation of Monocytic MDSCs
Shang, W., Gao, Y., Tang, Z., Zhang, Y., & Yang, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0443 · Cited by 110
The Emerging Role of YAP/TAZ in Tumor Immunity
Pan, Z., Tian, Y., Cao, C., & Niu, G. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0375 · Cited by 94
Xu, J., Yu, S., Wang, X., Qian, Y., Wu, W., Zhang, S., Zheng, B., Wei, G., Gao, S., Cao, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b03466 · Cited by 100
Khan, S., Mittal, S., McGee, K., Alfaro-Munoz, K. D., Majd, N., Balasubramaniyan, V., & de Groot, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061954 · Cited by 103
Metadata
- Authors
- Talmadge, J. E., & Gabrilovich, D. I.
- Affiliations
- University of Nebraska Medical Center (US)
- The Wistar Institute (US)
- Corresponding author
- Talmadge, James E.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 739-752
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4358792
- OpenAlex
- W2122403898
- Cited by
- 1,148
- References
- 197
- Citations by year
- 2026: 29 · 2025: 57 · 2024: 80 · 2023: 74 · 2022: 105 · 2021: 132 · 2020: 110 · 2019: 95 · 2018: 101 · 2017: 90 · 2016: 129 · 2015: 93 · 2014: 43 · 2013: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor microenvironment, T cell suppression, immune evasion, tumor progression, metastasis, multipotent progenitors
- MeSH terms
- Animals, Antigens, Differentiation, Antigens, Neoplasm, Cell Differentiation, Cell Biology, Hematopoiesis, Extramedullary, Humans, Leukemoid Reaction, Medical Oncology, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Chemokines, Cell Lineage, Tumor Escape, Hematopoietic Stem Cell Mobilization, Myeloid Cells, Myeloid Progenitor Cells, Multipotent Stem Cells, Tumor Burden, History, 20th Century, History, 21st Century, Mice, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.